Roxall Group
Roxall Group is a private European specialty pharmaceutical company that develops and manufactures allergen immunotherapy vaccines and allergy diagnostic products. It sells proprietary subcutaneous and sublingual vaccines, plus prick and patch diagnostics, to physicians, allergists, pharmacies, and wholesalers across 25+ countries, with manufacturing concentrated at a single GMP facility in Zamudio, Spain.
- Company typePrivate
- Founded1998
- HeadquartersZamudio, Spain
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Roxall Group does
Roxall Group is a privately-held international pharmaceutical company founded in 1998 in Hamburg, Germany (parent holding: ROXALL Medizin GmbH) and now operating its sole production and R&D center in Zamudio, Spain. The company develops and manufactures allergen immunotherapy vaccines and allergy diagnostic products, including polymerized allergenic extracts in depot suspension (Cluxin, Poliplus, Allergovac Depot), molecular allergoids polymerized with glutaraldehyde (Modigoid, Modigoid Plus), sublingual native-extract vaccines (Sulgen), and lyophilized hymenoptera venom vaccines (Abenox for Apis mellifera, Hymnox for Polistes, Vespa velutina and Vespula spp.). Its technology platform is anchored by in-house raw material production — controlled mite cultures, animal epithelia extracts, venom sac extraction, and fungal cultures — plus purification of major allergen proteins (Fel d 1, Alt a 1, Cup a 1, Profilin, LTP) for precision immunotherapy. The company cites 30+ years of R&D with an evidence base of 800+ applied research papers and 390+ publications.
ROXALL sells its proprietary immunotherapy vaccines and diagnostic products (prick tests, plus patch tests distributed via the Chemotechnique Diagnostics partnership) to physicians, allergists, pharmacies, and wholesalers across more than 25 countries spanning Europe, Central Asia, Latin America, North America, and Africa. Distribution is organized through the Roxvac B2B portal for pharmacies and wholesalers, a gated professional portal for healthcare professionals, a regional field sales force, and the ROXALL Allergy Academy training platform. Wholly-owned subsidiaries operate in Germany, Austria, Italy, Spain, Portugal, and Turkey, with the 2017 acquisition of BIAL Aristegui's allergy line providing the foundational R&D heritage. Manufacturing is concentrated at a single GMP-compliant facility in Zamudio. Pricing is not publicly disclosed and follows a quote/contract model typical of the pharmaceutical industry.
Roxall Group firmographics
Firmographics- Name
- Roxall Group
- Legal name
- Roxall Medicina España, S.A.
- Website
- https://roxall.es
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Roxall Group is a private European specialty pharmaceutical company that develops and manufactures allergen immunotherapy vaccines and allergy diagnostic products. It sells proprietary subcutaneous and sublingual vaccines, plus prick and patch diagnostics, to physicians, allergists, pharmacies, and wholesalers across 25+ countries, with manufacturing concentrated at a single GMP facility in Zamudio, Spain.
- Ownership category
- akta.pro rank
Roxall Group industry classification
Industry- Product category
- Allergen Immunotherapy Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)
- akta.pro secondary industries
- Autoimmune, Allergy & Specialized Immunology Diagnostics (HLAHAAAK), Combination Vaccines & Multivalent Formulations (HLAAAEAG)
Keywords
Where Roxall Group is headquartered
LocationHeadquarters
- HQ city
- Zamudio
- HQ country
- Spain
- HQ region
- Europe
Offices3 records
Markets served
Roxall Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Allergen Immunotherapy Vaccines: Sale of proprietary immunotherapy vaccine products (Cluxin, Poliplus, Allergovac Depot, Modigoid/Modigoid Plus, Sulgen, ABENOX, HYMNOX) to healthcare providers, pharmacies, and patients. Revenue is generated through product sales across subcutaneous and sublingual administration routes.
- Allergy Diagnostic Products: Sale of prick test allergenic extracts and distribution of patch test products (Chemotechnique Diagnostics) for allergy diagnosis, supporting both clinical and laboratory testing.
- Professional Services & Training: ROXALL Allergy Academy provides training activities, courses, congress events, and professional support tools to healthcare professionals, supporting adoption and ongoing education in allergen immunotherapy.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Roxall Group product offering
Product offeringCore offering
Roxall Group develops, manufactures, and distributes allergen immunotherapy vaccines and allergy diagnostic products at a sole GMP-compliant facility in Zamudio, Spain. The portfolio includes subcutaneous polymerized allergenic extracts in depot suspension (Cluxin, Poliplus, Allergovac Depot), molecular allergoid vaccines (Modigoid, Modigoid Plus), sublingual immunotherapies (Sulgen), lyophilized hymenoptera venom vaccines (Abenox, Hymnox), and allergy diagnostics (prick tests and Chemotechnique patch tests), distributed via pharmacy and wholesaler channels and prescribed by allergists and physicians.
Product overview
Roxall Group is an international pharmaceutical company specializing in allergen immunotherapy products. The product portfolio consists of immunotherapy vaccines (Cluxin, Poliplus, Allergovac Depot, Modigoid, Modigoid Plus, Sulgen) for subcutaneous and sublingual administration targeting respiratory allergies and hymenoptera venom hypersensitivity, diagnostic products (Prick Diagnosis, Patch Tests) for allergy testing, and the Roxvac patient/pharmacy portal for order management. The company operates primarily in Europe with production facilities in Zamudio, Spain, and maintains R&D focus on raw materials production (animal epithelia, mites, fungi), purified proteins (Fel d 1, Alt a 1, Cup a 1, Profilin, LTP), and biotechnology research.
Differentiator
Problem solved
Functional benefit
Brands
- RoxVac: Portal for pharmacies and wholesalers to track orders and access invoices
Products and services
- Cluxin Allergen immunotherapy vaccine of polymerized allergenic extracts formulated in depot suspension for subcutaneous administration, prescribed by allergists and physicians for respiratory allergies.
- Poliplus Allergen immunotherapy vaccine of polymerized allergenic extracts in depot suspension at double concentration for allergen mixtures, for subcutaneous administration.
- Allergovac Depot Vaccine of native allergenic extracts in depot suspension for subcutaneous administration in allergen immunotherapy.
- Modigoid Natural major allergen vaccine purified and polymerised with glutaraldehyde (molecular allergen) for subcutaneous immunotherapy with reduced IgE reactivity.
- Modigoid Plus Mixture of molecular allergoids with up to 3 additional polymerized extracts for subcutaneous immunotherapy, providing multi-allergen molecular precision therapy.
- Sulgen Vaccine of native allergenic extracts in glycerin solution for sublingual administration, offering a non-injective allergen immunotherapy route with single initiation and maintenance presentations.
- Abenox Lyophilized hymenoptera venom protein vaccine (Apis mellifera / honey bee) for subcutaneous immunotherapy of bee venom hypersensitivity.
- Hymnox Lyophilized hymenoptera venom protein vaccine for Polistes dominula, Polistes spp., Vespa velutina, Vespula germanica and Vespula vulgaris for subcutaneous immunotherapy of wasp venom hypersensitivity.
- Prick Diagnosis Allergenic extracts for allergy testing by prick skin test, covering mites, animal epithelia, fungi, pollens, poisons, solvents, and other allergens, used by allergists for diagnostic work-up.
- Patch Tests (Chemotechnique Diagnostics Distribution) Epicutaneous contact diagnostic patch tests distributed in Spain through the official Chemotechnique Diagnostics partnership, complementing the prick test portfolio for contact allergy diagnosis.
Quantifiable outcome
- 30% of Spanish population affected by allergy — addressable market for disease-modifying immunotherapy
- +2 more outcomes
Companies that use Roxall Group
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Roxall Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Roxall Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Chemotechnique DiagnosticsminorROXALL is an official distributor of Chemotechnique Diagnostics products in Spain, which includes patch tests and contactors for allergy diagnosis. ROXALL distributes the Chemotechnique catalog, handles orders, and forwards requests to [email protected]. This partnership complements ROXALL's prick test diagnostic portfolio with epicutaneous (patch) test capabilities.
Scale indicators6 records
Recent moves12 records
Expansion highlights6 records
Roxall Group competitors and assessment
Company assessmentDirect peers
- ALK-Abelló: ALK-Abelló is the global market leader in allergen immunotherapy, offering SCIT, SLIT tablets (Acarizax, Grazax, Itulazax), and diagnostics. It directly competes with ROXALL across European respiratory allergy and venom markets with substantially greater commercial scale.
- Allergy Therapeutics: Allergy Therapeutics is a UK-based specialty AIT company focused on allergy vaccination (Pollinex Quattro, Acarovac Plus, Oraltek) with strong DACH and Iberia presence via its Bencard Allergie subsidiary. It is a direct competitor in SCIT/SLIT and venom vaccines.
- LETI Pharma: LETI Pharma is a Spanish AIT specialist with a portfolio of subcutaneous and sublingual allergen vaccines and diagnostics. It is the most direct Iberian head-to-head competitor to ROXALL in Spain and Portugal and operates in similar distribution and physician channels.
- HAL Allergy: HAL Allergy is a Netherlands/Germany-headquartered AIT specialist offering SCIT, SLIT drops (Sublivac) and diagnostics, with strong positions in Northern Europe. It directly competes in the same physician channel as ROXALL and mirrors its European mid-sized specialty profile.
- Bencard Allergie: Bencard Allergie is Allergy Therapeutics' German AIT subsidiary focused on subcutaneous and sublingual allergen vaccines and diagnostics. It overlaps ROXALL's German footprint with a comparable specialty pharma positioning in allergy immunotherapy.
- Stallergenes Greer: Stallergenes Greer (part of Bertis) is a top-tier global allergen immunotherapy company with a broad SCIT/SLIT portfolio including Oralair. It competes head-to-head with ROXALL in Europe, especially France, Iberia, and Italy, with deeper resources and broader prescriber coverage.
- Lofarma: Lofarma is an Italian AIT company specializing in sublingual immunotherapy drops (Allergosystem, Lais) and allergoid preparations. ROXALL operates in the same Italian market with comparable sublingual/SCIT products, making it a near-direct niche peer.
Emerging players
- Biomay: Biomay is an Austrian biotech producing recombinant allergens and GMP-manufactured allergoid vaccines for therapeutic and diagnostic use. It overlaps ROXALL's molecular allergen purification focus (recombinant Fel d 1, Alt a 1) and is a relevant emerging peer.
- ASIT Biotech: ASIT Biotech is a Belgian clinical-stage biotech developing peptide-based allergen immunotherapy. It is a more R&D-focused emerging peer addressing the same AIT category as ROXALL's precision allergoid portfolio, though concentrated at an earlier commercialization stage.
Others
- Chemotechnique Diagnostics: Chemotechnique Diagnostics is the Swedish manufacturer of patch test/haptens distributed by ROXALL in Spain. Although not a direct competitor, it is a direct channel partner providing complementary diagnostic capabilities and an adjacent allergy diagnostics comparison point.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Roxall Group social profiles
Digital presenceRoxall Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roxall Group leadership team
Management profileNumber of profiles
Roxall Group subsidiaries and ownership
Company hierarchySubsidiaries5 records
Roxall Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roxall Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roxall Group
What does Roxall Group do?
Roxall Group develops, manufactures, and distributes allergen immunotherapy vaccines and allergy diagnostic products at a sole GMP-compliant facility in Zamudio, Spain. The portfolio includes subcutaneous polymerized allergenic extracts in depot suspension (Cluxin, Poliplus, Allergovac Depot), molecular allergoid vaccines (Modigoid, Modigoid Plus), sublingual immunotherapies (Sulgen), lyophilized hymenoptera venom vaccines (Abenox, Hymnox), and allergy diagnostics (prick tests and Chemotechnique patch tests), distributed via pharmacy and wholesaler channels and prescribed by allergists and physicians.
Is Roxall Group a public or private company?
Roxall Group is a private company. It is classified as private equity controlled and is currently operating.
When was Roxall Group founded?
Roxall Group was founded in 1998. It employs 101 to 250 people.
Where is Roxall Group based?
Roxall Group is headquartered in Zamudio, Spain, in the Europe region.
How does Roxall Group make money?
Three revenue lines are on record. Allergen Immunotherapy Vaccines are the primary driver. The others are allergy Diagnostic Products and professional Services & Training.
Who are Roxall Group's main competitors?
Direct peers on record are ALK-Abelló, Allergy Therapeutics, LETI Pharma, HAL Allergy, Bencard Allergie, Stallergenes Greer and Lofarma. Emerging players are Biomay and ASIT Biotech. Chemotechnique Diagnostics is listed as an others.
Does Roxall Group have an API?
No public API is recorded for Roxall Group.
What industry is Roxall Group in?
Roxall Group's product category is Allergen Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAAAEAI, Allergy Immunotherapy Biologics (allergen extracts, desensitization), with a secondary code of HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics. Its NAICS code is 325414 and its SIC code is 2836.